Backed by Science

Luminopiaâ„¢ One is a digital therapeutic developed closely with leading physicians and neuroscientists that has been validated through a series of clinical trials, including a prospective, randomized controlled trial.

Luminopia One has been approved by the FDA for prescription use, and is indicated for improvement in visual acuity in amblyopia patients aged 4-7.

Supporting scientific literature

Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia


Ophthalmology 2021. In Press.

Digital Therapeutic Improves Visual Acuity and Encourages High Adherence in Amblyopic Children in Open-Label Pilot Study


Journal of AAPOS 2021;25(2):87.e1-87.e6

Improved adherence and treatment outcomes with an engaging, personalized digital therapeutic in amblyopia


Scientific Reports 2020;10:8328.